Protocol Ledger

NCT06449222 · Phase II · ACTIVE NOT RECRUITING

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Interventional Phase II clinical trial protocol NCT06449222 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-26 Enrollment: 83 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06449222
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)83 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06449222
Protocol FieldVerified Registry Value
NCT IdentifierNCT06449222
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment83 participants (ACTUAL)
Registered Start Date2024-08-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI